With the US public markets virtually closed since 2022, merger and acquisition (M&A) is an attractive exit for biotechs and their shareholders. This session explores actionable strategies to plan for, build, and execute a successful M&A exit, and provide insights on what to expect once the transaction is complete.
- Hear from founders about their M&A journey and post-transaction experiences.
- Learn from strategics about how they assess potential M&A targets and what their internal workflow looks like.
- Understand the crucial role service providers play in the M&A process.
Gain insights into navigating a M&A exit, from early-stage planning to final execution, and company integration.
